Aortitis medical therapy

Aortitis Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Aortitis from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Aortitis medical therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
[1]
American Roentgen Ray Society Images of Aortitis medical therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
on Aortitis medical therapy
CDC on Aortitis medical therapy
medical therapy in the news
Blogs on Aortitis medical therapy
Directions to Hospitals Treating Aortitis
Risk calculators and risk factors for Aortitis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [2] Hibatullah Abdul Aleem, M.B.B.S[3]

Overview

Medical therapy for aortitis is directed by the underlying etiology and must be initiated promptly given the potential for life-threatening complications including aortic rupture, dissection, and end-organ ischemia. The major categories requiring distinct treatment approaches are: (1) large vessel vasculitis-associated aortitis, including giant cell arteritis (GCA) and Takayasu arteritis (TAK); (2) IgG4-related aortitis; and (3) infectious aortitis. Early antimicrobial therapy with broad spectrum coverage is indicated in infectious aortitis. The preferred agents include either cefotaxime, ciprofloxacin, penicillinase-resistant penicillins, or vancomycin. Surgical debridement is recommended among patients with gram-negative rod aortitis. A multidisciplinary approach involving rheumatology, vascular surgery, cardiology and infectious disease is recommended for all subtypes.

Medical Therapy

Infectious Aortitis

Suspected infectious aortitis should be promptly recognized and treated. Empiric antibiotic coverage is recommended for all patients pending culture results with agents providing adequate coverage for Staphylococcus spp. and gram-negative rods. Given the significant mortality associated with infectious aortitis treated with antibiotic therapy alone, particularly when gram-negative organisms are involved, surgical debridement With or without aneurysm repair is recommended (weak recommendation - data from case series not clinical trials). Treatment duration is 6 to 12 weeks following surgical debridement and clearance of blood cultures.

Antimicrobial Regimen

• Empiric Antimicrobial Therapy

• 1. Gram-negative coverage

• Preferred regimen (1): Cefotaxime sodium 1-2 g IV q8h
• Preferred regimen (2): Ciprofloxacin 400 mg IV q12h OR Ciprofloxacin 500-750 mg PO q12h OR Levofloxacin 500-750 mg IV/PO q24h

• 2. Staphylococcal coverage

• 2.1 Methicillin-sensitive Staphylococcus aureus (MSSA)

• Preferred regimen: Oxacillin 1-2 g IV/IM q4-6h OR Nafcillin 1-2 g IV/IM q4-6h OR Dicloxacillin 0.5-1 g IV/IM q4-6h
• Alternative regimen: Cefazolin 2 g IV q8h (preferred in penicillin-allergic patients without history of anaphylaxis)

• 2.2 Methicillin-resistant Staphylococcus aureus (MRSA)

• Preferred regimen:
  • 'Vancomycin 1 g (15 mg/kg) IV q12h (maximum dose 3-4 g/day)
  • as per the 2020 ASHP/IDSA/PIDS/SIDP consensus guideline: Vancomycin 15 to 20 mg/kg IV q8 to q12h, with AUC/MIC target 400 to 600.
• Alternative regimen Daptomycin 6 to 10 mg/kg IV q24h, particularly with elevated vancomycin MIC or vancomycin intolerance.

• Note: Dose of cefotaxime sodium should be decreased by 50% among patients with a creatinine clearance (CCr) of ≤ 20 mL/min. Ciprofloxacin should be used cautiously among patients with a CCr ≤ 50 mL/min or when given concomitantly with drugs whose metabolism may be altered.

Large Vessel Vasculitis-Associated Aortitis:

As per the 2021 ACR/Vasculitis Foundation Guidelines:

Giant Cell Arteritis (GCA)

1. Initial Therapy
   • Preferred regimen: Prednisone 40–60 mg PO daily in patients with newly diagnosed, active GCA without vision involvement.
   • Preferred regimen in patients with threatened or established vision loss: IV pulse methylprednisolone 500–1000 mg/day for 3 days, followed by high-dose oral prednisone 40–60 mg/day.
2. Adjunctive Biologic Therapy
   • Preferred regimen: Tocilizumab 162 mg SC weekly OR 162 mg SC every other week, in combination with a glucocorticoid taper, to achieve and maintain remission and reduce cumulative glucocorticoid exposure.
3. Steroid-Sparing Alternatives
   • Alternative regimen: Methotrexate 15 to 25 mg weekly may be considered when tocilizumab is contraindicated or unavailable.
4. Adjunctive Antiplatelet Therapy
   • Preferred regimen: Low-dose aspirin 81 mg PO daily, in the absence of contraindications, to reduce risk of ischemic complications.
5. Glucocorticoids should be tapered gradually over 12 to 18 months guided by clinical symptoms and inflammatory markers (ESR, CRP).
6. Long-term clinical and imaging surveillance is recommended in all patients given the risk of relapse and late aortic aneurysm formation.

Takayasu Arteritis

1. Initial Therapy
   • Preferred regimen: High-dose oral prednisone 1 mg/kg/day (maximum 60 mg/day) in patients with newly active, severe disease not previously on immunosuppression.
2. Adjunctive Immunosuppressive Therapy
   • Non-glucocorticoid immunosuppressive therapy is preferred over tocilizumab as initial adjunctive therapy and is added early to facilitate glucocorticoid tapering.
     • Preferred regimen (1): Methotrexate 15 to 25 mg PO weekly
     • Preferred regimen (2): Azathioprine 2 mg/kg PO daily
     • Preferred regimen (3): Mycophenolate mofetil 2 to 3 g PO daily
     • Preferred regimen (4)Leflunomide 20 mg PO daily
3. Therapy for Refractory Disease
   • In patients refractory to glucocorticoids and conventional immunosuppressants, TNF-α inhibitors are preferred over tocilizumab.
     • Preferred regimen (1): Infliximab 5 mg/kg IV at weeks 0, 2, 6, then every 4 to 8 weeks
     • Preferred regimen (2): Adalimumab 40 mg SC every other week
   • Alternative regimen: Tocilizumab 8 mg/kg IV every 4 weeks OR 162 mg SC weekly, particularly when TNF inhibitors are contraindicated.
4. Once remission is achieved and maintained for 6 to 12 months, gradual tapering off glucocorticoids is preferred over indefinite long-term therapy.

• Surgical or endovascular vascular intervention should be deferred until inflammation is controlled with medical therapy, where clinically feasible, to reduce restenosis and graft failure rates.

IgG4-Related Aortitis:

IgG4-related aortitis is treated as a fibroinflammatory disorder, with glucocorticoids as standard induction therapy and rituximab as an effective alternative or adjunctive agent. Urgent treatment is indicated given the risk of progressive aneurysm formation and dissection.

1. Initial Therapy
   • Preferred regimen: Oral prednisone 0.6 mg/kg/day (typically 30 to 40 mg/day) for 2 to 4 weeks, followed by a gradual taper over 3 to 6 months.
2. Alternative or Refractory Disease
   • Preferred regimen: Rituximab 1000 mg IV on day 1 and day 15 OR 375 mg/m² IV weekly for 4 doses, particularly in patients with contraindications to glucocorticoids, glucocorticoid-refractory disease, or high risk of glucocorticoid toxicity.
3. Maintenance with low-dose glucocorticoids or repeat rituximab infusions may be considered in patients with organ-threatening manifestations or high risk of relapse.

• Serial CTA or MRA should be performed to monitor aortic dimensions and response to therapy.